ConvaTec Group Plc
CNVVF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.35B
Close$
$1.83
40.6% downside
Current Fair Value
40.6% downsideOvervalued by 40.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.35 Billion |
|---|---|
| Enterprise Value | $7.99 Billion |
| Annual dividend | $0.08 |
| Dividend yield | 2.27% |
| Earnings per Share | $0.09 |
| Beta | 0.9 |
| Outstanding Shares | 1,953,694,374 |
Return
| Return on Equity | 23.76% |
|---|---|
| Return on Assets | 8.97% |
| Return on Invested Capital | 23.45% |
Valuation & Multiples
| P/E Ratio | 51.94 |
|---|---|
| PEG | -107.12 |
| Price to Sales | 1.54 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.65 |
| Enterprise Value to EBIT | 10.42 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 1.22 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.08
Consensus analyst estimateRevenue Estimate
$1.23 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
$0.12
Consensus analyst estimateRevenue Estimate
$1.33 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About ConvaTec Group Plc
10,910 employees
CEO: Jonathan Peter Mason
ConvaTec Group Plc is a global medical technology company focused on creating, producing, and distributing a wide array of healthcare products. Their offerings span several key areas: Advanced Wound Management: This includes specialized ...